// App-Quantinova.ai

562 : Goserelin plus tamoxifen versus tamoxifen alone in pre-or peri-menopausal patients with hormone receptor-positive early-stage breast cancer: A randomized, controlled clinical trial in China.

Researchers

Presenter

  • Hongjian Yang

Principal Investigators

  • Xingfei Yu

  • Xiangyun Zong

  • Daobao Chen

  • Xiaowen Ding

  • Yang Yu

  • Dehong Zou

  • Xiangming He

  • Weiliang Feng

  • Jie Chen

  • Wenju Mo

  • Chen Wang

Medical Centers

  • Zhejiang Cancer Hospital, Hangzhou, China

  • Zhejiang Cancer Hospital, Hangzhou, China

  • Shanghai the 6th Peoples Hospital, Shanghai, China

  • Zhejiang Cancer Hospital, Hangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Stromal interaction molecule 1

Drug/Treatment

  • Tamoxifen

  • Goserelin

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • NCT00827307

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved